- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01125644
Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis
Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective: primary objective Evaluation of the overall global clinical response based on secondary end points from 1 to 6 at the end of the therapy (Study day 14) and at the final visit at the end of the study - follow-up- (Study day 28) in comparison to the initial clinical state.
The evaluation will be based on: improvement/normalization in relation to the semi-quantitative scales at 3, 4 and 5 items or at opinion expressed as positive for at least 3 of the first 6 secondary end points.
secondary objectives
- Improvement on the basis of clinical symptoms;
- Antifungal efficacy from the cultures;
- Improvement on the basis of mycological blood testing;
- Improvement on the basis of laboratory diagnosis (hemogasanalysis, ESR, CPR);
- Improvement on the basis of radiological imaging (Rx, CAT HR,…);
- Improvement on the basis of endoscopic examination;
- Evaluate the plasma levels of SPK-843 after single dose and after multiple doses;
- Evaluate the safety in the administration of SPK-843.
Methodology: Open label multi center study
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Luigi Allegra, Ph.D
- Phone Number: 39 02 55033781
- Email: luigi.allegra@unimi.it
Study Contact Backup
- Name: Adolfo Gasparetto, Dr.
- Phone Number: 39 0429 652545
- Email: adolfogasparetto@nextrasearch.it
Study Locations
-
-
-
Milan, Italy, 20122
- Recruiting
- Ospedale Maggiore di Milano IRCCS Policlinico Dipartimento Malattie Cardiovascolari e Respiratorie
-
Contact:
- Luigi Allegra, Ph.D
- Phone Number: 39 02 55033781
- Email: luigi.allegra@unimi.it
-
Principal Investigator:
- Francesco Blasi, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:The following will be included in the study:
- Patients with proven fungal etiology confirmed by mycological culture test and by hystopathological exam ("patients with definite diagnosis"), or patients with fungal infection of which is difficult to determine the etiological agent but with diagnosis of deep mycosis based on blood testing for fungal infection and/or clinical radiological examination, and/or endoscopic clinical examination, clinical symptomatology ("patients with clinical diagnosis").
- Patients being treated with other anti-fungal drugs (i) showing a poor response to the treatment at least after 5 days of administration of the anti-fungal drug, (ii) that have had an adverse reaction to the drug prejudicing its use, determining the risk/benefit ratio unfavorable to the patient.
- Patients between 18 and 75 years of age.
- Patients able to understand the content of the Informed Consent and willing to participate in the study.
- Male and female patients.
- Patients initially admitted to the hospitals identified for this clinical study.
- Informed Consent.
Exclusion Criteria:
- Patients being treated with other anti-fungal drugs with improving clinical symptoms or with an unclear clinical course.
- Patients with intra-venous catheter and hospitalized with a diagnosis of fungemia but without clinical symptomatology twelve hours after the removal of the catheter.
- Patients with serious deep mycosis with low change of clinical efficacy (with a high probability of death event), or with serious concomitant illnesses or with complications, which may make difficult a safety evaluation of the treatment object of this study.
- Patients with a history of allergy to drugs like AMPH-B or with serious allergic reactions to drugs (shock after administration of drugs different from antifungals).
Patients with serious hepatic, and/or renal, and/or cardiac failure or basic lung disease or with functionality of the organs with the following criteria:
- AST (GOT) or ALT (GPT) higher five (5) times the highest normal value or 200 UI/L;
- Blood creatinine higher than 2,0 mg/dl;
- Proteinuira (qualitative test) 3+ or greater, or a total urinary excretion of proteins (quantitative test) of 3,5 g/day or higher;
- Hyperkalemia or hypokalemia or with a basic level of sodium of 6,0 mEq/L or greater or less than 2,5 mEq/L;
- Hyperlipidemia with a basic value of total cholesterol greater than 1,5 times the highest normal values or 300 mg/dl, triglycerides higher than twice the highest normal values or 300 mg/dl;
- Patients that require the infusion of leucocytes;
- Patients with arterial thrombosis or with serious coagulative dysfunctions;
- Patients with diabetes mellitus associated with ketosis ;
- Pregnant women or women who intend to become pregnant, women in purperium, or breast feeding;
- Patients that participated in a clinical study (with any type of drugs, including anti-cancer drugs) or that have been recruited for observational clinical studies with pharmaceutical agents a month before the beginning of the treatment with SPK-843;
- Patients who, according to the doctor, are not considered fit to be recruited in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Single Arm
Patients are males and females between 18 and 75 years of age with proven fungal etiology confirmed by mycological culture test and by hystopathological exam ("patients with definite diagnosis"), or patients with fungal infection of which is difficult to determine the etiological agent but with diagnosis of deep mycosis based on blood testing for fungal infection and/or clinical radiological examination, and/or endoscopic clinical examination, clinical symptomatology ("patients with clinical diagnosis").
|
SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the overall global clinical response
Time Frame: 28 days
|
Evaluation of the overall global clinical response based on secondary end points from 1 to 6 at the end of the therapy (Study day 14) and at the final visit at the end of the study - follow-up- (Study day 28) in comparison to the initial clinical state.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the safety in the administration of SPK-843.
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Luigi Allegra, Ph.D., Ospedale Maggiore di Milano IRCCS Policlinico
- Principal Investigator: Francesco Blasi, MD, Ospedale Maggiore di Milano IRCCS Policlinico
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPK-843-03/01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cryptococcosis or Aspergillosis Infections
-
PfizerCompletedCandidiasis | Aspergillosis | CryptococcosisTaiwan
-
Medstar Health Research InstituteEnzon Pharmaceuticals, Inc.WithdrawnInvasive CryptococcosisUnited States
-
Imagine InstituteRecruitingInvasive Aspergillosis | Cerebral AspergillosisFrance
-
Astellas Pharma IncWithdrawnAspergillosis/Blood | Aspergillosis/InvasiveUnited States
-
Nantes University HospitalCompleted
-
Poitiers University HospitalCompleted
-
Postgraduate Institute of Medical Education and...RecruitingAllergic Bronchopulmonary Aspergillosis | Chronic Pulmonary AspergillosisIndia
-
University of Colorado, DenverUniversity of California, Davis; University of GeorgiaRecruitingCandidiasis | Aspergillosis | Cryptococcosis | Pneumocystis Jirovecii Infection | PneumocystisUnited States
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedCystic Fibrosis | Allergic Bronchopulmonary AspergillosisUnited States
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedCystic Fibrosis | Allergic Bronchopulmonary AspergillosisUnited States
Clinical Trials on SPK-843
-
Chong Kun Dang PharmaceuticalCompletedAlopeciaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedAlopeciaKorea, Republic of
-
Spark TherapeuticsActive, not recruitingLysosomal Storage Diseases | Glycogen Storage Disease Type II | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase DeficiencyUnited States, Canada, Netherlands, France, Denmark, Germany, Italy, United Kingdom
-
Rambam Health Care CampusUnknownGroup A- 23 Implant Using Switch Platform -SPK Abutment. | Group B- 22 Implant Using the Traditional -CPK Abutment.Israel
-
Spark TherapeuticsCompletedHematologic Diseases | Blood Coagulation Disorders, Inherited | Coagulation Protein Disorders | Hemorrhagic Disorders | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Gene Therapy | Blood Coagulation Disorder | Gene Transfer | Adeno-Associated Virus (AAV) | Factor VIII (FVIII) | Factor VIII (FVIII)... and other conditionsUnited States
-
PfizerActive, not recruitingHemophilia BUnited States, Canada, Australia, Turkey
-
Spark TherapeuticsActive, not recruitingHemophilia AUnited States, Canada, Australia
-
Spark TherapeuticsCompletedHemophilia AUnited States, Australia, Canada, Israel, Thailand
-
Second Affiliated Hospital of Guangzhou Medical...CompletedDiabetic Nephropathy | Perioperative/Postoperative Complications | Transplant ComplicationChina